Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18026698 | 0.73 | ACACB (0.43) | CYP3A4CYP2C9CYP2C19ESR1ESR2 | |
| SCHEMBL16835636 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2NPSR1ALDH1A1KMT2AMEN1 | |
| SCHEMBL31726115 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2NPSR1ALDH1A1KMT2AMEN1 | |
| SCHEMBL8022630 | 0.70 | PSMB8 (0.57) | CYP3A4ESR1ESR2 | |
| SCHEMBL14858822 | 0.70 | KMT2A (0.39) | SMN1; SMN2NPSR1ALDH1A1KMT2AMEN1 | |
| SCHEMBL18026590 | 0.70 | ACACB (0.47) | KMT2AKDM4ENPC1MAPTCYP2C9 | |
| SCHEMBL5419860 | 0.69 | ESR2 (0.49) | SMN1; SMN2ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL2594871 | 0.68 | KEAP1 (0.50) | SMN1; SMN2NPSR1ALDH1A1KMT2AMEN1 | |
| SCHEMBL8798366 | 0.68 | ALDH1A1 (0.49) | SMN1; SMN2NPSR1ALDH1A1KMT2AMEN1 | |
| SCHEMBL7716540 | 0.67 | SMN1; SMN2 (0.49) | SMN1; SMN2NPSR1ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010528-B1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| EP-2010528-B1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| US-8710048-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-8710048-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-8710048-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-8173689-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173689-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173689-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-20100280006-A1 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2010-11-04 | — | — | US | disclosed |
| US-7553854-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-2010528-A2 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | Novartis Pharma AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-20080045528-A1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG | 2008-02-21 | — | — | US | disclosed |
| US-20080045528-A1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG | 2008-02-21 | — | — | US | disclosed |
| US-20080045528-A1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG | 2008-02-21 | — | — | US | disclosed |
| WO-2007121484-A2 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121484-A2 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | CSF1R, CSF3R, FLT3 | SMN1; SMN2 2510/4885NPSR1 412/4885ALDH1A1 1292/4885 |
| US-20100280006-A1 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | CSF1R, CSF3R, FLT3 | SMN1; SMN2 2510/4885NPSR1 412/4885ALDH1A1 1292/4885 |
| US-20080045528-A1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | CSF1R, CSF3R, FLT3 | SMN1; SMN2 2510/4885NPSR1 412/4885ALDH1A1 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.